Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 1/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.50 |
| ▸ | IGF1R | P08069 | 16/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27169598 | 0.93 | LRRK2 (0.48) | IKBKETBK1LRRK2IGF1RCDK1 | |
| SCHEMBL27169623 | 0.91 | LRRK2 (0.46) | IKBKETBK1LRRK2IGF1RCDK1 | |
| SCHEMBL27169600 | 0.91 | LRRK2 (0.56) | IKBKETBK1LRRK2CDK2 | |
| SCHEMBL27169585 | 0.90 | LRRK2 (0.50) | IKBKETBK1LRRK2CDK2 | |
| SCHEMBL29754145 | 0.89 | IGF1R (0.48) | IGF1RCDK1CDK2CDK8CDK7 | |
| SCHEMBL22544824 | 0.89 | IGF1R (0.48) | IGF1RCDK1CDK2CDK8CDK7 | |
| SCHEMBL29754122 | 0.87 | IGF1R (0.46) | IGF1RCDK1CDK2CDK8CDK7 | |
| SCHEMBL27275136 | 0.87 | IGF1R (0.46) | IGF1RCDK1CDK2CDK8CDK7 | |
| SCHEMBL27169601 | 0.87 | LRRK2 (0.59) | IKBKETBK1LRRK2CDK2 | |
| SCHEMBL22544822 | 0.87 | IGF1R (0.53) | IGF1RCDK1CDK2CDK8CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20240083882-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | JAK3, JAK1, JAK2 | IKBKE 317/4885TBK1 70/4885LRRK2 1384/4885 |
| US-20240083882-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK3, JAK1, JAK2 | IKBKE 320/4885TBK1 65/4885LRRK2 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.